B-cell receptor signaling in diffuse large B-cell lymphoma. - Wikidata - thesis-toulmin - TriplyDB

B-cell receptor signaling in diffuse large B-cell lymphoma.

B-cell receptor signaling in diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q35218042

about

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.The significance of FOXP1 in diffuse large B-cell lymphoma.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Inhibition of Canonical NF-κB Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts.Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis.Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Targeting CK2-driven non-oncogene addiction in B-cell tumors.Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas.30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Mutational landscape of B-cell post-transplant lymphoproliferative disorders.miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.The genomic landscape of adult T cell leukemia/lymphoma.Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.Clinical applications of genome studies.Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.Aggressive lymphoma 2016: revision of the WHO classification.Identification of cellular responses to low-dose radiation by the profiling of phosphorylated proteins in human B-lymphoblast IM-9 cells.Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.

P2860

Q27304386-EDE35DD7-D633-4B69-ACD9-BF4CE8E66807 Q28067817-BD4BE56A-D224-4C12-8349-2992DD5745AF Q30275206-3EFB8008-553D-43C7-BFD4-C35DD7CA8A52 Q33618634-74581E25-5A64-4AA9-8F1F-AA07DBD06D90 Q33622342-7E1C2969-D5FD-4BE9-ADFD-06B3499B3893 Q33701845-569469BC-30B4-4345-B7FC-A7839C7D6A9B Q33729711-D551CF6D-04DC-4EF9-AD0F-DF973BD93258 Q34047455-51170DEB-877C-4509-B9C5-20CF98B5265D Q34543066-952C9CC4-7D95-4D10-B8A0-7738495E44B3 Q35887748-239B4F77-9315-4A2B-B230-A897AF1B4A6E Q36192439-A3F2459D-D638-43D9-9CED-47A3E98793D9 Q36438238-EB9A2022-D882-4F18-A33D-01350482F3CA Q36920426-99DAD91B-3BDB-45F3-8DE0-2DD30752AFAD Q37142412-8B792FAF-3763-48F4-B7C3-DC2DD7A66B06 Q37271866-BABEAB54-FC2A-4146-95B2-3B56567F9E70 Q37624527-70118CB3-0E31-47E4-AEEC-D8608011FFDC Q37650198-4ACB7F61-2B49-4A3A-87F5-01877B9C0BEB Q38430117-1CAFA195-9AF9-4FFF-8CBE-D2060A0F5E29 Q38594364-F77864B9-F777-43ED-B5CA-909726D50C59 Q38646971-215D2A73-4B14-4DE9-911A-D59A97892625 Q38710832-BC2F4C93-A2BF-40FA-B93E-49AEFC4C9B86 Q38728157-FB4A6FCB-EDDA-44BC-B12A-6F079408940A Q38787141-C1B6C52E-E4B1-4499-843C-A9390ECB0779 Q38797342-56F38D72-A095-4407-92E4-C9F9A75DD910 Q38798801-5563EC4F-4B3F-4B3E-8026-2F93882A8813 Q39086011-4761CA03-3574-432B-A03A-B1027F9DC52C Q39091822-3357E220-ADBB-49FC-8EB7-F9B13D3F3F0C Q39147488-3A9FB47D-FF57-4A13-8A83-E2D759415A35 Q39325783-907C90BE-C321-4A66-BB9F-5A707138DB3A Q40238236-CECBEA7A-3B27-4FE4-82EF-289987C9A965 Q40340268-1DA4759E-D7B8-4B29-84B4-187C42EF8567 Q40935286-EF12ABFB-FC96-4478-A8C2-91A44A7D9F4C Q41004137-597C35C4-1EC6-4CE8-9956-639B611CAFB4 Q41692369-265BFD1E-5F20-4298-8046-622042FBC3A6 Q42284390-965A0109-8D15-45C3-B218-D5123C297618 Q45594363-38B80A49-C9E3-4650-A0A6-E68DCD642E7C Q47123563-5E36DB55-9F8A-4F4C-BD64-9194AD5432B6 Q47842853-30F1D6E0-806D-42BA-B01F-5756AA889C31 Q47886065-8F73ACA9-28AB-46CE-B09E-D25411270318 Q48136905-1ED5E4A4-DAF2-4D2A-AE31-2891F6C3F1D1

P2860

B-cell receptor signaling in diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q35218042

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

B-cell receptor signaling in diffuse large B-cell lymphoma.

@ast

B-cell receptor signaling in diffuse large B-cell lymphoma.

@en

type

label

B-cell receptor signaling in diffuse large B-cell lymphoma.

@ast

B-cell receptor signaling in diffuse large B-cell lymphoma.

@en

prefLabel

B-cell receptor signaling in diffuse large B-cell lymphoma.

@ast

B-cell receptor signaling in diffuse large B-cell lymphoma.

@en

P1433

Q35218042-3EB246EC-1593-4B66-AD05-5E5EEE6CB796

P1476

Q35218042-DB55FE61-1B2D-4F52-A505-8B7228C18797

P2093

Q35218042-142B6E82-3FE4-48DC-8AC3-9CDCD897CFFF

Q35218042-22613CE2-09B6-48B4-A66F-0CE5B9CDBD26

Q35218042-F7EB536B-96E0-4CFD-9A7B-56123BC1DEC8

Q35218042-F7F42D06-D7F7-4623-B7C0-4F0CA377731C

P2860

Q35218042-001A9A18-09F5-441D-8EF7-A2486E79E7D3

Q35218042-025AF2EF-ACB1-4F2C-B7F4-B8FF74409446

Q35218042-03F9B3A3-0D76-4589-8E66-7F04A64E6C64

Q35218042-0946D83C-0187-4CB9-A371-136D3A3B8A32

Q35218042-0B44982D-9DBE-45B8-BA41-6D01F46EF528

Q35218042-0C5C7E06-F7F4-4731-922A-35C9A7004CDC

Q35218042-0F320A6E-1DA1-47B9-A1EB-0B760435C9DE

Q35218042-12AC6715-C4D2-4CFE-8187-A234373F3807

Q35218042-1819E24C-DE88-4246-871D-FFCB48939A53

Q35218042-187E46FB-A514-49CE-821A-3CB57309DEC4

P304

Q35218042-B3FED7F1-B912-4BB5-8BB6-9CC534AD1F8A

P31

Q35218042-59ABA5B9-4221-413B-A1AF-4A7D4CA4195C

P356

Q35218042-061FF93E-9F9E-44C0-9FE5-73549877E6C4

P433

Q35218042-10883829-18BD-483F-9773-2A88AE17F4BF

P478

Q35218042-2B52568F-2CE4-4351-823E-8D39E9D74F08

P577

Q35218042-6F7A0602-D74F-405A-953F-FFFCED46FDF0

P5875

Q35218042-C9DCB271-E974-45D9-864D-60746819B9A2

P698

Q35218042-E9E2EC33-02FF-4B06-882F-922CB39B991C

P932

Q35218042-3290D410-5088-4A60-970F-29B5D692D297

P356

J.SEMINHEMATOL.2015.01.008

P1433

Seminars in Hematology

P1476

B-cell receptor signaling in diffuse large B-cell lymphoma.

@en

P2093

Arthur L Shaffer

http://www.w3.org/2001/XMLSchema#string

James D Phelan

http://www.w3.org/2001/XMLSchema#string

Louis M Staudt

http://www.w3.org/2001/XMLSchema#string

Ryan M Young

http://www.w3.org/2001/XMLSchema#string

P2860

A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Oncogenically active MYD88 mutations in human lymphoma

Lyn tyrosine kinase: accentuating the positive and the negative

P304

77-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMINHEMATOL.2015.01.008

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273309313

http://www.w3.org/2001/XMLSchema#string

P698

25805587

http://www.w3.org/2001/XMLSchema#string

P932

4374122

http://www.w3.org/2001/XMLSchema#string